Illumina/$ILMN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Ticker
$ILMN
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
9,000
ISIN
US4523271090
Website
Illumina Metrics
BasicAdvanced
$14B
-
-$6.08
1.35
-
Price and volume
Market cap
$14B
Beta
1.35
52-week high
$156.66
52-week low
$68.70
Average daily volume
2.3M
Financial strength
Current ratio
1.856
Quick ratio
1.344
Long term debt to equity
85.726
Total debt to equity
110.093
Interest coverage (TTM)
6.01%
Profitability
EBITDA (TTM)
958
Gross margin (TTM)
68.62%
Net profit margin (TTM)
-22.27%
Operating margin (TTM)
13.40%
Effective tax rate (TTM)
-8.78%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
4.95%
Return on equity (TTM)
-23.85%
Valuation
Price to revenue (TTM)
3.309
Price to book
6.06
Price to tangible book (TTM)
14.69
Price to free cash flow (TTM)
16.515
Free cash flow yield (TTM)
6.06%
Free cash flow per share (TTM)
546.54%
Growth
Revenue change (TTM)
-3.47%
Earnings per share change (TTM)
-25.41%
3-year revenue growth (CAGR)
-2.34%
10-year revenue growth (CAGR)
8.16%
3-year earnings per share growth (CAGR)
10.10%
10-year earnings per share growth (CAGR)
7.71%
What the Analysts think about Illumina
Analyst ratings (Buy, Hold, Sell) for Illumina stock.
Bulls say / Bears say
Illumina's strategic partnership with the Broad Institute aims to advance single-cell sequencing, potentially expanding its market reach and technological capabilities. (bloomberglaw.com)
The company has projected an acceleration in revenue growth to high single digits by 2027, indicating a positive long-term outlook. (markets.businessinsider.com)
Illumina's cost-cutting measures, including plans to reduce annualized run rate expenses by more than $100 million in 2023, demonstrate a commitment to improving profitability. (finance.yahoo.com)
China's ban on imports of Illumina's genetic sequencing instruments, effective from March 4, 2025, could significantly impact the company's revenue, as the Chinese market accounts for about 7% of its sales. (reuters.com)
Illumina's 2025 revenue forecast of $4.28 billion to $4.4 billion falls short of Wall Street estimates, signaling potential challenges in meeting market expectations. (reuters.com)
The company is facing a $1.47 billion goodwill impairment charge related to its spin-off of Grail, indicating financial strain from previous acquisitions. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Illumina Financial Performance
Revenues and expenses
Illumina Earnings Performance
Company profitability
Illumina News
AllArticlesVideos
Insiders Have Been Aggressively Buying These 5 Stocks
24/7 Wall Street·2 hours ago
Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling
Business Wire·2 days ago
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Illumina stock?
Illumina (ILMN) has a market cap of $14B as of June 20, 2025.
What is the P/E ratio for Illumina stock?
The price to earnings (P/E) ratio for Illumina (ILMN) stock is 0 as of June 20, 2025.
Does Illumina stock pay dividends?
No, Illumina (ILMN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Illumina dividend payment date?
Illumina (ILMN) stock does not pay dividends to its shareholders.
What is the beta indicator for Illumina?
Illumina (ILMN) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.